MX378409B - Regimen de dosificacion para un inhibidor selectivo alfa-isomorfo de fosfatidilinositol 3-quinasa. - Google Patents

Regimen de dosificacion para un inhibidor selectivo alfa-isomorfo de fosfatidilinositol 3-quinasa.

Info

Publication number
MX378409B
MX378409B MX2016007376A MX2016007376A MX378409B MX 378409 B MX378409 B MX 378409B MX 2016007376 A MX2016007376 A MX 2016007376A MX 2016007376 A MX2016007376 A MX 2016007376A MX 378409 B MX378409 B MX 378409B
Authority
MX
Mexico
Prior art keywords
alpha
kinase inhibitor
isomorphic
dosage regimen
compound
Prior art date
Application number
MX2016007376A
Other languages
English (en)
Other versions
MX2016007376A (es
Inventor
Christian Rene Schnell
Christine Fritsch
Cristian Massacesi
Tomaso Emmanuelle Di
Marie- Caroline GERMA
Ranjana Tavorath
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49876516&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX378409(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2016007376A publication Critical patent/MX2016007376A/es
Publication of MX378409B publication Critical patent/MX378409B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención hace referencia a un compuesto inhibidor selectivo de la isomorfo alfa de la fosfatidilinositol 3-quinasa de formula (I) o una sal farmacéuticamente aceptable del mismo, para su uso en métodos útiles que tratan o previenen una enfermedad proliferativa en pacientes en necesidad del mismo mediante la administración oral de una cantidad terapéuticamente efectiva de dicho compuesto por al menos dos ciclos de cinco días consecutivos, en donde dicho compuesto no es administrado al paciente por un periodo de alrededor de dos días o alrededor de tres días entre dicho ciclo de cinco días consecutivos.
MX2016007376A 2013-12-06 2014-12-03 Regimen de dosificacion para un inhibidor selectivo alfa-isomorfo de fosfatidilinositol 3-quinasa. MX378409B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13306679 2013-12-06
PCT/IB2014/066558 WO2015083101A1 (en) 2013-12-06 2014-12-03 Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor

Publications (2)

Publication Number Publication Date
MX2016007376A MX2016007376A (es) 2017-05-11
MX378409B true MX378409B (es) 2025-03-10

Family

ID=49876516

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007376A MX378409B (es) 2013-12-06 2014-12-03 Regimen de dosificacion para un inhibidor selectivo alfa-isomorfo de fosfatidilinositol 3-quinasa.

Country Status (22)

Country Link
US (4) US20170000778A1 (es)
EP (2) EP4000619A1 (es)
JP (1) JP2016539149A (es)
KR (1) KR20160095035A (es)
CN (1) CN105979947A (es)
AU (2) AU2014358773A1 (es)
BR (1) BR112016011811A2 (es)
CA (1) CA2930359C (es)
CL (1) CL2016001361A1 (es)
DK (1) DK3076969T3 (es)
ES (1) ES2899167T3 (es)
HU (1) HUE057092T2 (es)
IL (1) IL245709B (es)
MX (1) MX378409B (es)
PH (1) PH12016501026A1 (es)
PL (1) PL3076969T3 (es)
PT (1) PT3076969T (es)
RU (1) RU2680246C1 (es)
SI (1) SI3076969T1 (es)
TN (1) TN2016000179A1 (es)
TW (1) TWI666019B (es)
WO (1) WO2015083101A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3002954A1 (en) * 2015-11-02 2017-05-11 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
WO2018060833A1 (en) * 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
GB202010627D0 (en) * 2020-07-10 2020-08-26 Qbd (Qs-Ip) Ltd Blocking method

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041077B2 (ja) 1976-09-06 1985-09-13 喜徳 喜谷 １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
US4323581A (en) 1978-07-31 1982-04-06 Johnson & Johnson Method of treating carcinogenesis
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4923986A (en) 1987-03-09 1990-05-08 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance K-252
US4904768A (en) 1987-08-04 1990-02-27 Bristol-Myers Company Epipodophyllotoxin glucoside 4'-phosphate derivatives
EP0383919A4 (en) 1988-02-04 1992-08-05 Kyowa Hakko Kogyo Co., Ltd. Staurosporin derivatives
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
AU2866992A (en) 1991-10-10 1993-05-03 Schering Corporation 4'-(n-substituted-n-oxide)staurosporine derivatives
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
JPH07505124A (ja) 1991-11-08 1995-06-08 ザ ユニバーシティ オブ サザン カリフォルニア ニューロトロフィン活性増強のためのｋ−２５２化合物を含む組成物
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5948898A (en) 1992-03-16 1999-09-07 Isis Pharmaceuticals, Inc. Methoxyethoxy oligonucleotides for modulation of protein kinase C expression
US5621100A (en) 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
US5756494A (en) 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
ATE378406T1 (de) 1992-08-31 2007-11-15 Ludwig Inst Cancer Res Vom mage-3-gen en abgeleitetes und von hla-a1 präsentiertes, isoliertes nonapeptid und dessen anwendungen
US5674867A (en) 1992-09-21 1997-10-07 Kyowa Hakko Kogyo Co., Ltd. Indolocarbazole derivatives and therapeutic method for stimulating megakaicyocyte production
ES2309119T3 (es) 1992-10-28 2008-12-16 Genentech, Inc. Utilizacion de antagonistas del factor de crecimiento celular vegf.
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
ES2149276T3 (es) 1993-07-15 2000-11-01 Minnesota Mining & Mfg Imidazo(4,5-c)piridin-4-aminas.
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
ES2236702T3 (es) 1993-12-23 2005-07-16 Eli Lilly And Company Inhibidores de la proteina quinasa c.
US5587459A (en) 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
EP0817775B1 (en) 1995-03-30 2001-09-12 Pfizer Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
WO1997007081A2 (en) 1995-08-11 1997-02-27 Yale University Glycosylated indolocarbazole synthesis
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
EA000710B1 (ru) 1995-12-08 2000-02-28 Жансен Фармасетика Н.В. (имидазол-5-ил)метил-2-хинолиноновые производные, ингибирующие фарнезилпротеин-трансферазу
KR100447918B1 (ko) 1996-07-25 2005-09-28 동아제약주식회사 대장을포함한위장관보호작용을갖는플라본및플라바논화합물
EP0917569B1 (en) 1996-08-02 2005-11-09 GeneSense Technologies Inc. Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6126965A (en) 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
CA2294244A1 (en) 1997-07-12 1999-01-21 Cancer Research Campaign Technology Limited Cyclin dependent kinase inhibiting purine derivatives
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
DK2020408T3 (da) 1998-05-29 2013-09-30 Sugen Inc Pyrrol-substitueret 2-indolinon som proteinkinaseinhibitor
US20030083242A1 (en) 1998-11-06 2003-05-01 Alphonse Galdes Methods and compositions for treating or preventing peripheral neuropathies
AU784045B2 (en) 1999-06-25 2006-01-19 Genentech Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
AU6014900A (en) 1999-07-13 2001-01-30 Kyowa Hakko Kogyo Co. Ltd. Staurosporin derivatives
IL149034A0 (en) 1999-11-05 2002-11-10 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
ES2531547T3 (es) 1999-12-06 2015-03-17 Geistlich Pharma Ag Uso de taurolidina o el taurultamo para la fabricación de un medicamento para el tratamiento de tumores
CO5280092A1 (es) 2000-02-15 2003-05-30 Sugen Inc Indolinas susutituidas con pirroles inhibidoras de proteinquinasas
AU2001253427B2 (en) 2000-04-12 2007-02-08 Genaera Corporation A process for the preparation of 7.alpha.-hydroxy 3-aminosubstituted sterols using intermediates with an unprotected 7.alpha.-hydroxy group
TWI307339B (en) 2000-06-30 2009-03-11 Glaxo Group Ltd Quinazoline ditosylate salt comprounds
ATE309996T1 (de) 2000-09-11 2005-12-15 Chiron Corp Chinolinonderivate als tyrosin-kinase inhibitoren
US6677450B2 (en) 2000-10-06 2004-01-13 Bristol-Myers Squibb Company Topoisomerase inhibitors
JP4323167B2 (ja) 2001-01-16 2009-09-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 分泌タンパク質を発現する細胞の単離
WO2002062826A1 (fr) 2001-02-07 2002-08-15 Vadim Viktorovich Novikov Procede de fabrication des peptides
US20040186172A1 (en) 2001-07-02 2004-09-23 Houssam Ibrahim Oxaliplatin active substance with a very low content of oxalic acid
KR100484504B1 (ko) 2001-09-18 2005-04-20 학교법인 포항공과대학교 쿠커비투릴 유도체를 주인 분자로서 포함하고 있는 내포화합물 및 이를 포함한 약제학적 조성물
US20030134846A1 (en) 2001-10-09 2003-07-17 Schering Corporation Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors
EP1485082A4 (en) 2002-02-19 2009-12-30 Xenoport Inc PROCESS FOR THE SYNTHESIS OF PROMEDICAMENTS FROM 1-ACYL-ALKYL DERIVATIVES AND CORRESPONDING COMPOSITIONS
WO2003082272A1 (en) 2002-03-29 2003-10-09 Chiron Corporation Substituted benzazoles and use thereof as raf kinase inhibitors
US6727272B1 (en) 2002-07-15 2004-04-27 Unitech Pharmaceuticals, Inc. Leflunomide analogs for treating rheumatoid arthritis
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
AU2003300021A1 (en) 2002-12-27 2004-07-29 Chiron Corporation Thiosemicarbazones as anti-virals and immunopotentiators
US8193185B2 (en) 2003-01-21 2012-06-05 Novartis Vaccines And Diagnostics, Inc. Use of tryptanthrin compounds for immune potentiation
ES2423800T3 (es) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgánicos para la inmunopotenciación
MX383644B (es) * 2005-02-18 2025-03-14 Abraxis Bioscience Llc Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion.
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
MX360157B (es) * 2010-11-08 2018-10-24 Novartis Ag Uso de derivados de 2-carboxamida-cicloamino-urea en el tratamiento de enfermedades dependientes de egfr o de enfermedades que han adquirido resistencia a los agentes que tienen como objetivo los miembros de la familia egfr.
KR20140033432A (ko) * 2011-06-21 2014-03-18 노파르티스 아게 (s)-피롤리딘-1,2-디카르복실산 2-아미드 1-(｛4-메틸-5-[2-(2,2,2-트리플루오로-1,1-디메틸-에틸)-피리딘-4-일]-티아졸-2-일｝-아미드)의 다형체
EP2601965A1 (en) * 2011-12-06 2013-06-12 Apeiron Biologics AG Compositions for preventing or treating adverse reactions of EGFR inhibition
CN104349779A (zh) 2012-05-16 2015-02-11 诺华股份有限公司 Pi-3激酶抑制剂的剂量方案

Also Published As

Publication number Publication date
AU2014358773A1 (en) 2016-06-02
HK1223549A1 (zh) 2017-08-04
BR112016011811A2 (pt) 2017-08-08
CA2930359A1 (en) 2015-06-11
WO2015083101A1 (en) 2015-06-11
US20180078540A1 (en) 2018-03-22
AU2017245292B2 (en) 2018-09-27
PT3076969T (pt) 2021-11-23
HUE057092T2 (hu) 2022-04-28
PH12016501026A1 (en) 2016-07-04
MX2016007376A (es) 2017-05-11
US10434092B2 (en) 2019-10-08
EP4000619A1 (en) 2022-05-25
TN2016000179A1 (en) 2017-10-06
ES2899167T3 (es) 2022-03-10
IL245709B (en) 2021-03-25
RU2680246C1 (ru) 2019-02-19
PL3076969T3 (pl) 2022-01-17
TW201609096A (zh) 2016-03-16
AU2017245292A1 (en) 2017-11-02
US20170000778A1 (en) 2017-01-05
SI3076969T1 (sl) 2021-12-31
CA2930359C (en) 2022-03-01
IL245709A0 (en) 2016-07-31
DK3076969T3 (da) 2021-11-22
US20200069670A1 (en) 2020-03-05
TWI666019B (zh) 2019-07-21
JP2016539149A (ja) 2016-12-15
CN105979947A (zh) 2016-09-28
EP3076969B1 (en) 2021-09-01
EP3076969A1 (en) 2016-10-12
CL2016001361A1 (es) 2017-02-10
US20210196696A1 (en) 2021-07-01
KR20160095035A (ko) 2016-08-10

Similar Documents

Publication Publication Date Title
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
MX2016001400A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
EA201790088A1 (ru) Ингибиторы syk
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
MX2013012588A (es) Inhibidores de cinasa.
PH12016502355A1 (en) Pharmaceutical composition
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
PH12016502353A1 (en) Pharmaceutical composition
MX381440B (es) Composicion farmaceutica para tratar colitis ulcerativa.
TW201613577A (en) Pharmaceutical combinations
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
ME02405B (me) Spojevi pirazola као inhibitori sglt1
BR112019004236A2 (pt) compostos para tratar doenças associadas a uma disfunção mitocondrial
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
PH12016501026A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
BR112014030288A8 (pt) composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila
AR097890A1 (es) Compuestos de urea
BR112016008060A8 (pt) composto, formulação farmacêutica, processo para preparar um composto de fórmula (i), método para preparação de um composto, uso do composto ou sal farmaceuticamente aceitável do mesmo